Summit Therapeutics Inc 8-K, filed Oct 4, 2022
Summit Therapeutics Inc. (SMMT)
8-K
2022-10-04
For: 2022-09-28
View Original
Added on
April 09, 2026
About this 8-K
Summit Therapeutics Inc filed this 8-K on October 4, 2022, reporting on events of September 28, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 28, 2022
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: 617 -514-7149
| Not applicable | ||
| (Former Name or Former Address, If Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. | ||||
On September 28, 2022, Summit Therapeutics Inc. (the “Company”) determined that it will seek partners or a divestiture of ridinilazole as the path forward for the clinical development of the asset. Ridinilazole is the Company’s Phase III product candidate for the treatment of patients with Clostridioides difficile infection (“C. diff. infection” or “CDI”). As a result of this determination, the Company will discontinue its only active study for ridinilazole, a pediatric clinical trial evaluating ridinilazole for treating adolescent patients with CDI.
As previously communicated, the Company held a Type C meeting with the US Food & Drug Administration (“FDA”) during which the FDA and Summit discussed a possible pathway in which to advance ridinilazole forward with the goal of achieving marketing authorization. This pathway would involve at least one additional registrational trial, for which we will seek a partner to perform.
Further, the Company plans to present the data associated with ridinilazole’s Phase III clinical trial, Ri-CoDIFy, at IDWeek 2022 later this month.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits
Exhibit Number | Description | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| SUMMIT THERAPEUTICS INC. | ||||||||
| Date: October 4, 2022 | By: | /s/ Ankur Dhingra | ||||||
| Chief Financial Officer | ||||||||
| (Principal Financial Officer) | ||||||||